BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 24531230)

  • 1. 2-[N-Alkyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines as anticancer agents inhibitors of folate enzymes.
    Piras S; Carta A; Briguglio I; Corona P; Paglietti G; Luciani R; Costi MP; Ferrari S
    Eur J Med Chem; 2014 Mar; 75():169-83. PubMed ID: 24531230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofolate reductase and thymidylate synthase and as potential antitumor agents.
    Gangjee A; Lin X; Kisliuk RL; McGuire JJ
    J Med Chem; 2005 Nov; 48(23):7215-22. PubMed ID: 16279780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational modification of the lead molecule: Enhancement in the anticancer and dihydrofolate reductase inhibitory activity.
    Kaur J; Kaur S; Singh P
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1936-40. PubMed ID: 26979156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, docking studies and biological evaluation of novel dihydro-1,3,5-triazines as human DHFR inhibitors.
    Zhou X; Lin K; Ma X; Chui WK; Zhou W
    Eur J Med Chem; 2017 Jan; 125():1279-1288. PubMed ID: 27886545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
    Gangjee A; Adair OO; Queener SF
    J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of novel 6-substituted pyrrolo [3,2-d] pyrimidine analogues as antifolate antitumor agents.
    Tian C; Wang M; Han Z; Fang F; Zhang Z; Wang X; Liu J
    Eur J Med Chem; 2017 Sep; 138():630-643. PubMed ID: 28711701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
    Gangjee A; Adair O; Queener SF
    J Med Chem; 1999 Jul; 42(13):2447-55. PubMed ID: 10395486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An innovative strategy for dual inhibitor design and its application in dual inhibition of human thymidylate synthase and dihydrofolate reductase enzymes.
    Arooj M; Sakkiah S; Cao Gp; Lee KW
    PLoS One; 2013; 8(4):e60470. PubMed ID: 23577115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2,4-diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases.
    Gangjee A; Vasudevan A; Queener SF; Kisliuk RL
    J Med Chem; 1996 Mar; 39(7):1438-46. PubMed ID: 8691474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quinoxaline chemistry. Part 11. 3-Phenyl-2[phenoxy- and phenoxymethyl]-6(7) or 6,8-substituted quinoxalines and N-[4-(6(7)-substituted or 6,8-disubstituted-3-phenylquinoxalin-2-yl)hydroxy or hydroxymethyl] benzoylglutamates. Synthesis and evaluation of in vitro anticancer activity and enzymatic inhibitory activity against dihydrofolate reductase and thymidylate synthase.
    Corona P; Vitale G; Loriga M; Paglietti G; Costi MP
    Farmaco; 1998 Jul; 53(7):480-93. PubMed ID: 9836461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quinoxaline chemistry. Part 15. 4-[2-Quinoxalylmethylenimino]-benzoylglutamates and -benzoates, 4-[2-quinoxalylmethyl-N-methylamino]-benzoylglutamates as analogues of classical antifolate agents. Synthesis, elucidation of structures and in vitro evaluation of antifolate and anticancer activities.
    Loriga M; Piras S; Paglietti G; Costi MP; Venturelli A
    Farmaco; 2003 Jan; 58(1):51-61. PubMed ID: 12595037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent.
    Gangjee A; Yu J; McGuire JJ; Cody V; Galitsky N; Kisliuk RL; Queener SF
    J Med Chem; 2000 Oct; 43(21):3837-51. PubMed ID: 11052789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis.
    Liu Y; Zhang C; Zhang H; Li M; Yuan J; Zhang Y; Zhou J; Guo H; Zhao L; Du Y; Wang L; Ren L
    Eur J Med Chem; 2015 Mar; 93():142-55. PubMed ID: 25668494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
    Gangjee A; Vidwans AP; Vasudevan A; Queener SF; Kisliuk RL; Cody V; Li R; Galitsky N; Luft JR; Pangborn W
    J Med Chem; 1998 Aug; 41(18):3426-34. PubMed ID: 9719595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
    Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
    Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells.
    Marverti G; Ligabue A; Paglietti G; Corona P; Piras S; Vitale G; Guerrieri D; Luciani R; Costi MP; Frassineti C; Moruzzi MS
    Eur J Pharmacol; 2009 Aug; 615(1-3):17-26. PubMed ID: 19446547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triazine-benzimidazole hybrids: anticancer activity, DNA interaction and dihydrofolate reductase inhibitors.
    Singla P; Luxami V; Paul K
    Bioorg Med Chem; 2015 Apr; 23(8):1691-700. PubMed ID: 25792141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of novel antifolate analogs as potential anticancer treatment.
    Stoicescu DF; Rotaru M
    Anticancer Agents Med Chem; 2013 Feb; 13(2):364-72. PubMed ID: 23157590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological activities of classical N-[4-[2-(2-amino-4-ethylpyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and its 6-methyl derivative as potential dual inhibitors of thymidylate synthase and dihydrofolate reductase and as potential antitumor agents.
    Gangjee A; Yu J; Kisliuk RL; Haile WH; Sobrero G; McGuire JJ
    J Med Chem; 2003 Feb; 46(4):591-600. PubMed ID: 12570380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of N-(5,7-diamino-3-phenyl-quinoxalin-2-yl)-3,4,5-substituted anilines and N-[4[(5,7-diamino-3-phenylquinoxalin-2-yl)amino]benzoyl]-l-glutamic acid diethyl ester: evaluation of in vitro anti-cancer and anti-folate activities.
    Corona P; Loriga M; Costi MP; Ferrari S; Paglietti G
    Eur J Med Chem; 2008 Jan; 43(1):189-203. PubMed ID: 17532099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.